Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect

Targeting B-cell receptor signalling using Bruton tyrosine kinase (BTK) inhibitors (BTKis) has become a highly successful treatment modality for B-cell malignancies, especially for chronic lymphocytic leukaemia. However, long-term administration of BTKis can be complicated by adverse on- and/or off-...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Haoran, Guo, Hao, Yang, Jingyi, Liu, Yanyan, Liu, Xingchen, Zhang, Qing, Zhou, Keshu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9493169/
https://www.ncbi.nlm.nih.gov/pubmed/36138486
http://dx.doi.org/10.1186/s40164-022-00315-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9493169/
https://www.ncbi.nlm.nih.gov/pubmed/36138486
http://dx.doi.org/10.1186/s40164-022-00315-9

Ejemplares similares